Wednesday, July 16, 2025 7/16/2025

Ubiquitin pathway modulators as novel antituberculosis drugs

Award Number: R43AI191788
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/16/2025
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

Ubiquitin pathway modulators as novel antituberculosis drugs - New approaches are needed to treat NIAID priority pathogens, including Mycobacterium tuberculosis (Mtb). Emerging drug-resistance in Mtb poses a significant threat to global health, generating a pressing need to develop innovative therapeutics with the potential to avoid the rapid evolution of drug resistance. One novel approach is to harness host defense mechanisms to treat both drug-sensitive and drug-resistant tuberculosis (TB). A key observation that may lead to new combination therapies is that we have identified important roles for autophagy (ATG) proteins in resistance to Mtb specifically via degradative autophagy killing the organism. These new findings, in the setting of the extreme medical need for new approaches to treat TB, led to this new SBIR application to fully leverage prior discoveries and to focus on TB and multidrug-resistant (MDR)-TB in response to NIH and public health priorities. As a master regulator of autophagic degradation of mitochondria, Parkin E3 ligase is an important protective factor against Mtb. Parkin E3 ligase promotes clearance of Mtb in macrophage infection models. As such, activation of Parkin is expected to have antituberculosis therapeutic effect. Pogenra’s UbiProTM drug discovery platform was employed to discover novel, potent and selective Parkin activators. We demonstrated that Parkin activators robustly inhibited growth of Mtb in macrophages. In this Phase I grant, we propose evaluate Parkin activators for their antimycobacterial efficacy in cellular and animal models of tuberculosis and perform mechanism of action studies. The ultimate commercial goal of this project is the development of small molecule Parkin activators as novel drugs that could treat tuberculosis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $302,421 )
2025	2025	PROGENRA INC	271A GREAT VALLEY PARKWAY	MALVERN	PA	19355	CHESTER	USA	Allergy and Infectious Diseases Research	000	1	5/16/2025	NEW	$302,421
														Subtotal = $302,421

Grand Total All Awards = $302,421

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Ubiquitin pathway modulators as novel antituberculosis drugs

Award Number: R43AI191788

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/16/2025

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer